Allschwil, Switzerland, February 09, 2026
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment.
David Veitch, Basilea's Chief Executive Officer, stated: "We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant and increasing demand for novel antifungal therapies and Cresemba's clinical value for patients facing life-threatening invasive mold infections in this region. We are grateful to our partner Pfizer for their ongoing commitment to making Cresemba available to patients in need."
Cresemba is marketed in more than 75 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2024 and September 2025 amounted to USD 693 million, a 27 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1
About Cresemba (isavuconazole)
Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering more than 100 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and many additional countries, including in the Asia Pacific region.5
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland | |
| Phone | +41 61 606 1102 |
| media_relations@basilea.com investor_relations@basilea.com | |
This press release can be downloaded from www.basilea.com.
References
- IQVIA Analytics Link, September 2025. In-market sales reported as moving annual total (MAT) in US dollar.
- European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: February 08, 2026]
- Summary of Product Characteristics (SmPC) Cresemba: https://www.medicines.org.uk/emc/search?q=cresemba [Accessed: February 08, 2026]
- Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: February 08, 2026]
- The registration status and approved indications may vary from country to country.
Attachment
- Press release (PDF)
